Profusa (NASDAQ:PFSA) Stock Rating Lowered by Wall Street Zen

Profusa (NASDAQ:PFSA) was downgraded by stock analysts at Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Profusa currently has an average rating of “Sell”.

Profusa Stock Performance

NASDAQ:PFSA opened at $2.01 on Friday. The company has a market cap of $2.47 million, a price-to-earnings ratio of -0.90 and a beta of -0.14. Profusa has a fifty-two week low of $1.88 and a fifty-two week high of $180.00. The company’s 50-day moving average price is $7.33.

Profusa (NASDAQ:PFSA) last posted its quarterly earnings results on Wednesday, November 19th. The company reported ($52.50) EPS for the quarter.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.